Gapping up
In reaction to strong earnings/guidance: MHR +11.7%, RLGT +11.5%, JBL +4.3%, WOR +3.2%, SCHL +0.5%
M&A news: LPDX +62.4% (to be acquired by LabCorp (LH) for a purchase price of $5.25 per share in cash), VOD +1.1% (cont M&A spec with ATT (T))
Other news: RNN +13.2% (receives FDA orphan drug designation for RX-3117 in treatment of pancreatic cancer), AIXG +13.1% (receives large multiple tool order from China -- one of the largest orders the Company has ever received), ECTE +12% (provides update; workforce reduction due to the suspension of operations comprised ~70% of Echo's workforce), CYBR +11.3% (cont momentum higher following yest's IPO), XGTI +7.8% (announced purchase agreements for up to $16 mln with Lincoln Park Capital Fund), LXRX +7.4% (still checking), CREG +5.7% (cont strength following yest's 29% move higher), HAS +4.5% (co and Discovery Communications (DISCA) announced The Hub Network will become Discovery Family Channel effective Oct 13, 2014), HAWK +3.8% (favorable commentary on Wednesday's Mad Money), MNKD +3.3% (announced closing of global licensing agreement with Sanofi (SNY)), VRX +2.4% (co's unit Bausch + Lomb and Nicox's glaucoma candidate VESNEO meets primary endpoint in Phase 3 studies), GPRO +2.1% (still checking, HTC released video yesterday -- revealing GoPro-like camera), XXII +1.9% (granted meeting with FDA to advance development of a potential modified risk cigarette), FLEX +1.3% (following JBL results), MU +1% (trading higher ahead of eanings tonight)
Analyst comments: TC +2.2% (upgraded to Sector Perform from Sector Underperform at Scotia Capital), JD +2% (initiated with a Outperform at Macquarie), TI +2% (reinstated with a Overweight at JP Morgan), SLB +0.9% (upgraded to Outperform from Sector Perform at Iberia)
In reaction to strong earnings/guidance: MHR +11.7%, RLGT +11.5%, JBL +4.3%, WOR +3.2%, SCHL +0.5%
M&A news: LPDX +62.4% (to be acquired by LabCorp (LH) for a purchase price of $5.25 per share in cash), VOD +1.1% (cont M&A spec with ATT (T))
Other news: RNN +13.2% (receives FDA orphan drug designation for RX-3117 in treatment of pancreatic cancer), AIXG +13.1% (receives large multiple tool order from China -- one of the largest orders the Company has ever received), ECTE +12% (provides update; workforce reduction due to the suspension of operations comprised ~70% of Echo's workforce), CYBR +11.3% (cont momentum higher following yest's IPO), XGTI +7.8% (announced purchase agreements for up to $16 mln with Lincoln Park Capital Fund), LXRX +7.4% (still checking), CREG +5.7% (cont strength following yest's 29% move higher), HAS +4.5% (co and Discovery Communications (DISCA) announced The Hub Network will become Discovery Family Channel effective Oct 13, 2014), HAWK +3.8% (favorable commentary on Wednesday's Mad Money), MNKD +3.3% (announced closing of global licensing agreement with Sanofi (SNY)), VRX +2.4% (co's unit Bausch + Lomb and Nicox's glaucoma candidate VESNEO meets primary endpoint in Phase 3 studies), GPRO +2.1% (still checking, HTC released video yesterday -- revealing GoPro-like camera), XXII +1.9% (granted meeting with FDA to advance development of a potential modified risk cigarette), FLEX +1.3% (following JBL results), MU +1% (trading higher ahead of eanings tonight)
Analyst comments: TC +2.2% (upgraded to Sector Perform from Sector Underperform at Scotia Capital), JD +2% (initiated with a Outperform at Macquarie), TI +2% (reinstated with a Overweight at JP Morgan), SLB +0.9% (upgraded to Outperform from Sector Perform at Iberia)